The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Lackner Mark since 2020.
This trader's CIK number is 1777413.
At the time of last reporting, Lackner Mark was the Chief Scientific Officer of Zentalis Pharmaceuticals, Inc.. (stock ticker symbol ZNTL).
Also see all insider trading activities at Zentalis Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | ZNTL | 0 | $0 | 14,368 | $24,598 | 0 | $0 |
| 2024 | ZNTL | 0 | $0 | 1,585 | $18,290 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | IDYA | 0 | $0 | 4,501 | $88,434 | 3,500 | $22,659 |
| 2020 | IDYA | 0 | $0 | 7,968 | $116,186 | 7,123 | $40,873 |
1. Zentalis Pharmaceuticals, Inc. (ZNTL)
2. Ideaya Biosciences, Inc. (IDYA)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-02-03 | ZNTL | Sale | 14,368 | 1.71 | 24,598 |
| 2024-02-02 | ZNTL | Sale | 1,585 | 11.54 | 18,290 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-02-08 | IDYA | Option Ex | 300 | 6.98 | 2,094 |
| 2021-02-09 | IDYA | Option Ex | 1,104 | 6.98 | 7,705 |
| 2021-02-10 | IDYA | Option Ex | 596 | 6.98 | 4,160 |
| 2021-02-08 | IDYA | Sale | 300 | 21.01 | 6,303 |
| 2021-02-09 | IDYA | Sale | 1,104 | 21.05 | 23,234 |
| 2021-02-10 | IDYA | Sale | 596 | 21.00 | 12,516 |
| 2021-01-26 | IDYA | Option Ex | 1,500 | 5.80 | 8,700 |
| 2021-01-26 | IDYA | Sale | 2,501 | 18.55 | 46,381 |
| 2020-06-16 | IDYA | Option Ex | 6,750 | 5.80 | 39,150 |
| 2020-06-17 | IDYA | Option Ex | 373 | 4.62 | 1,723 |
| 2020-06-16 | IDYA | Sale | 6,750 | 14.93 | 100,764 |
| 2020-06-17 | IDYA | Sale | 373 | 19.91 | 7,427 |
| 2020-06-02 | IDYA | Sale | 845 | 9.46 | 7,995 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Lackner Mark (Chief Scientific Officer of Zentalis Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.